SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Emergence of SARS-CoV-2 variants like 501Y.V2 (B.1.351) poses challenges to COVID-19 vaccine efficacy.
• Understanding the immune response to these variants is crucial for developing effective vaccines.

Approach:

• Examined antibody response in patients hospitalized with COVID-19 in South Africa during 501Y.V2 predominance.
• Assessed binding and neutralizing antibody titers against 501Y.V2 and other SARS-CoV-2 variants.
• Evaluated cross-reactivity of antibodies from 501Y.V2-infected patients.

Key Points:

• Patients infected with 501Y.V2 demonstrated robust antibody titers against this variant.
• Antibodies from 501Y.V2 infections showed significant cross-reactivity with the original SARS-CoV-2 strain.
• Sera from 501Y.V2-infected individuals effectively neutralized the 501Y.V3 (P.1) variant.

Conclusions:

• The antibody response to the 501Y.V2 variant exhibits broad specificity.
• Vaccines incorporating the 501Y.V2 sequence may induce more cross-reactive immune responses, potentially improving protection against multiple SARS-CoV-2 variants.